Clostridium paraputrificum bacteremia in a 64-year-old woman with colon carcinoma

Anaerobe. 2023 Jun:81:102716. doi: 10.1016/j.anaerobe.2023.102716. Epub 2023 Feb 10.

Abstract

Here we report a case of bacteremia caused by Clostridium paraputrificum in a 64-year-old woman with colon carcinoma and gastrointestinal disease. Using the new EUCAST 2022 clinical breakpoints for Clostridium perfringens, the isolate was susceptible to metronidazole and vancomycin, but resistant to benzylpenicillin, meropenem, and clindamycin. Thus, treatment with metronidazole should be considered in all patients with Clostridium bacteremia until antibiotic susceptibility is determined to minimize the risk of treatment failure.

Keywords: 16S rRNA gene sequencing; Bacteremia; Clostridium paraputrificum; Colon carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / diagnosis
  • Bacteremia* / drug therapy
  • Carcinoma* / drug therapy
  • Clostridium
  • Clostridium Infections* / diagnosis
  • Clostridium Infections* / drug therapy
  • Colon
  • Female
  • Humans
  • Metronidazole / therapeutic use
  • Middle Aged

Substances

  • Metronidazole
  • Anti-Bacterial Agents

Supplementary concepts

  • Clostridium paraputrificum